As of close of business last night, Shockwave Medical Inc.’s stock clocked out at $328.19, down -0.44% from its previous closing price of $329.64. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 1803896 shares were traded. SWAV stock price reached its highest trading level at $329.64 during the session, while it also had its lowest trading level at $328.01.
Ratios:
To gain a deeper understanding of SWAV’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 74.18. For the most recent quarter (mrq), Quick Ratio is recorded 10.73 and its Current Ratio is at 11.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
On March 27, 2024, CL King started tracking the stock assigning a Buy rating and target price of $368.
On September 29, 2023, UBS started tracking the stock assigning a Neutral rating and target price of $218.UBS initiated its Neutral rating on September 29, 2023, with a $218 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 26 ’24 when Zacharias Isaac sold 4,000 shares for $287.67 per share. The transaction valued at 1,150,680 led to the insider holds 56,818 shares of the business.
FRANCIS LAURA sold 1,500 shares of SWAV for $450,000 on Mar 26 ’24. The Director now owns 3,551 shares after completing the transaction at $300.00 per share. On Mar 06 ’24, another insider, WATKINS FRANK T, who serves as the Director of the company, sold 2,000 shares for $253.65 each. As a result, the insider received 507,294 and left with 4,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SWAV now has a Market Capitalization of 12.31B and an Enterprise Value of 12.09B. As of this moment, Shockwave’s Price-to-Earnings (P/E) ratio for their current fiscal year is 85.00, and their Forward P/E ratio for the next fiscal year is 53.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 65.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.81 while its Price-to-Book (P/B) ratio in mrq is 18.16. Its current Enterprise Value per Revenue stands at 16.56 whereas that against EBITDA is 63.12.
Stock Price History:
Over the past 52 weeks, SWAV has reached a high of $331.58, while it has fallen to a 52-week low of $157.00. The 50-Day Moving Average of the stock is 272.16, while the 200-Day Moving Average is calculated to be 229.24.
Shares Statistics:
It appears that SWAV traded 939.84K shares on average per day over the past three months and 2.91M shares per day over the past ten days. A total of 36.99M shares are outstanding, with a floating share count of 36.62M. Insiders hold about 2.07% of the company’s shares, while institutions hold 94.94% stake in the company. Shares short for SWAV as of Mar 15, 2024 were 1.79M with a Short Ratio of 2.16, compared to 1.92M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.78% and a Short% of Float of 6.23%.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.98 for the current quarter, with a high estimate of $1.24 and a low estimate of $0.83, while EPS last year was $1.03. The consensus estimate for the next quarter is $1.2, with high estimates of $1.5 and low estimates of $1.07.
Analysts are recommending an EPS of between $6.18 and $4.09 for the fiscal current year, implying an average EPS of $4.85. EPS for the following year is $6.18, with 13 analysts recommending between $7.19 and $5.3.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $207.69M. It ranges from a high estimate of $210.1M to a low estimate of $205M. As of the current estimate, Shockwave Medical Inc.’s year-ago sales were $147.31M, an estimated increase of 41.00% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $226.67M, an increase of 25.80% less than the figure of $41.00% in the same quarter last year. There is a high estimate of $230.06M for the next quarter, whereas the lowest estimate is $223.73M.
A total of 13 analysts have provided revenue estimates for SWAV’s current fiscal year. The highest revenue estimate was $925.03M, while the lowest revenue estimate was $917.4M, resulting in an average revenue estimate of $920.88M. In the same quarter a year ago, actual revenue was $730.23M, up 26.10% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.17B and the low estimate is $1.08B. The average revenue growth estimate for next year is up 23.00% from the average revenue estimate for this year.
